First AD

Second AD

The Role of BTK Inhibition in CSU

Video content above is prompted by the following:

We previously discussed the role that BTK plays in mediating mast cell degranulation. Why does this make BTK an ideal target for CSU treatment?

Evolving Perspectives and Treatment Strategies in Chronic Spontaneous Urticaria 

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

Bruton's tyrosine kinase (BTK) is integral in the signaling pathways that lead to mast cell degranulation, a key process in chronic spontaneous urticaria (CSU). Targeting BTK can potentially inhibit this degranulation, reducing the release of histamines and other inflammatory mediators responsible for CSU symptoms. By focusing on BTK, treatments can more precisely modulate the immune response, offering a targeted therapeutic approach. This specificity may lead to improved efficacy and reduced side effects compared to broader immunosuppressive therapies.

Panelists discuss how Bruton tyrosine kinase’s (BTK) role in mediating mast cell degranulation makes it an ideal target for chronic spontaneous urticaria (CSU) treatment, as inhibiting BTK could effectively reduce histamine release and its associated symptoms.

Bringing CSU Back Under The House of Dermatology

Understanding the Chronicity of CSU

The Psychosocial Impact of CSU

The Pathogenesis of CSU

Tips on Diagnosing CSU

Less Is More: Diagnostic Testing for CSU

Disease Severity and Delays in Treatment in CSU

The Role of Dermatologists in Treating CSU

Treatment Approaches and the Limitations of Antihistamines for CSU

Steroids and Immunosuppressive Agents for CSU

Novel Therapeutics in Development for CSU

The Importance of Patient Education and Shared Decision-Making in CSU

The Role of BTK Inhibitors in the Evolving CSU Treatment Landscape

Unmet Needs in CSU Management

Key Takeaways and Future Directions in CSU Care